Mark E. Robson
Impact in
- Cancer Research top 0.1%
- Cancer Genomics and Diagnostics
- Breast Cancer Treatment Studies
- Genetics top 0.05%
- BRCA gene mutations in cancer
Papers in
- Co-authors
- Kenneth Offit (110 shared papers)Susan M. Domchek (58 shared papers)Jaya M. Satagopan (12 shared papers)Nadine Tung (29 shared papers)Larry Norton (51 shared papers)Judy E. Garber (30 shared papers)Jeff Boyd (19 shared papers)Jeffrey N. Weitzel (16 shared papers)
- Journals
- Journal of Clinical Oncology (114 papers)Cancer Research (29 papers)Breast Cancer Research and Treatment (22 papers)Cancer (15 papers)Annals of Oncology (14 papers)
- Partner nations
- United StatesUnited KingdomCanada
In The Last Decade
Mark E. Robson
392 papers receiving 20.1k citations
Mark E. Robson's Hit Papers
Peers
Comparison fields: 5 of 185
- Cancer Research 4.7k
- Genetics 8.3k
- Oncology 6.8k
- Reproductive Medicine 1.7k
- Pathology and Forensic Medicine 2.5k
Countries citing papers authored by Mark E. Robson
This map shows the geographic impact of Mark E. Robson's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Mark E. Robson with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Mark E. Robson more than expected).
Fields of papers citing papers by Mark E. Robson
This network shows the impact of papers produced by Mark E. Robson. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Mark E. Robson. The network helps show where Mark E. Robson may publish in the future.
Co-authors
The 25 scholars most cited alongside Mark E. Robson, linked wherever they have co-authored with each other. Click a name or a connecting line to browse the papers they share.
All Works
Showing the 20 most-cited of 420 papers — load more, or switch the sort, to bring in the rest.
| # | Work | ||
|---|---|---|---|
| 1 | Olaparib for Metastatic Breast Cancer in Patients with a Germline BRCA Mutation Hit paper breakdown → | 2017 | 2256 |
| 2 | Oral poly(ADP-ribose) polymerase inhibitor olaparib in patients with BRCA1 or BRCA2 mutations and advanced breast cancer: a proof-of-concept trial Hit paper breakdown → | 2010 | 1348 |
| 3 | Risk-Reducing Salpingo-oophorectomy in Women with aBRCA1orBRCA2Mutation Hit paper breakdown → | 2002 | 963 |
| 4 | Gene-Panel Sequencing and the Prediction of Breast-Cancer Risk Hit paper breakdown → | 2015 | 611 |
| 5 | A note on competing risks in survival data analysis Hit paper breakdown → | 2004 | 574 |
| 6 | American Society of Clinical Oncology Policy Statement Update: Genetic and Genomic Testing for Cancer Susceptibility Hit paper breakdown → | 2015 | 546 |
| 7 | Therapy-Related Clonal Hematopoiesis in Patients with Non-hematologic Cancers Is Common and Associated with Adverse Clinical Outcomes Hit paper breakdown → | 2017 | 545 |
| 8 | OlympiAD final overall survival and tolerability results: Olaparib versus chemotherapy treatment of physician’s choice in patients with a germline BRCA mutation and HER2-negative metastatic breast cancer Hit paper breakdown → | 2019 | 523 |
| 9 | 2000 | 422 | |
| 10 | 2008 | 415 | |
| 11 | 2013 | 404 | |
| 12 | Genome doubling shapes the evolution and prognosis of advanced cancers Hit paper breakdown → | 2018 | 358 |
| 13 | 2010 | 331 | |
| 14 | Association of KIT exon 9 mutations with nongastric primary site and aggressive behavior: KIT mutation analysis and clinical correlates of 120 gastrointestinal stromal tumors. | 2003 | 301 |
| 15 | 2003 | 282 | |
| 16 | 1998 | 253 | |
| 17 | 2003 | 229 | |
| 18 | 2010 | 219 | |
| 19 | 2002 | 209 | |
| 20 | 2020 | 197 |
About Mark E. Robson
Mark E. Robson is a scholar working on Genetics, Oncology, Cancer Research, Pulmonary and Respiratory Medicine and Molecular Biology, having authored 420 papers that have together received 20.8k indexed citations. Recurring topics across this work include BRCA gene mutations in cancer (172 papers), PARP inhibition in cancer therapy (71 papers), Cancer Genomics and Diagnostics (59 papers), Advanced Breast Cancer Therapies (56 papers), DNA Repair Mechanisms (39 papers), Breast Cancer Treatment Studies (37 papers), Genetic factors in colorectal cancer (31 papers) and Ovarian cancer diagnosis and treatment (23 papers). The work is most often cited by research in Cancer Research (4.7k citations), Genetics (8.3k citations), Oncology (6.8k citations), Reproductive Medicine (1.7k citations) and Pathology and Forensic Medicine (2.5k citations). Mark E. Robson has collaborated with scholars based in United States, United Kingdom and Canada. Frequent co-authors include Kenneth Offit, Susan M. Domchek, Jaya M. Satagopan, Nadine Tung, Larry Norton, Judy E. Garber, Jeff Boyd, Jeffrey N. Weitzel, Binghe Xu and Norikazu Masuda. Their work appears in journals such as Journal of Clinical Oncology, Cancer Research, Breast Cancer Research and Treatment, Cancer and Annals of Oncology.
Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.